Filing Flows › Adma Biologics (ADMA) › Guidance & outlook
Adma Biologics (ADMA) guidance and outlook
Adma Biologics (ADMA) raised some and lowered other parts of its guidance on Nov 4, 2026: Revenue $530M for FY2026; Net income $180M for FY2026; EBITDA $275M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $530M | lowered |
| Net income | FY2026 | $180M | lowered |
| EBITDA | FY2026 | $275M | lowered |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Adma Biologics' latest quarter
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Adma Biologics raise or lower its guidance?
Adma Biologics (ADMA) raised some and lowered other parts of its guidance on Nov 4, 2026: Revenue $530M for FY2026; Net income $180M for FY2026; EBITDA $275M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.